NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.17% | -11.61% | -26.59% | -54.35% | -52.62% |
| Total Depreciation and Amortization | 51.41% | 75.22% | 117.65% | 248.98% | 189.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.16% | 12.71% | 32.53% | 49.77% | 94.66% |
| Change in Net Operating Assets | -163.97% | 1,460.00% | 140.30% | 100.87% | 192.81% |
| Cash from Operations | -0.96% | -7.98% | 7.71% | -33.97% | -22.60% |
| Capital Expenditure | 94.49% | 94.32% | 91.53% | 86.27% | -3.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -92.31% | -92.31% |
| Cash from Investing | 94.47% | 94.43% | 91.64% | 86.15% | -7.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -84.21% | -8.00% | 26.67% | 38.71% | 44.12% |
| Issuance of Common Stock | 11.40% | 133.50% | -0.43% | 6.00% | -27.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.71% | -- | -- | -214.23% | -73.28% |
| Cash from Financing | 12.14% | 132.18% | -0.75% | -35.43% | -29.50% |
| Foreign Exchange rate Adjustments | 147.66% | 179.90% | 198.27% | -462.50% | -414.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.81% | 134.57% | 804.40% | -211.59% | -176.88% |